Design Therapeutics Inc (DSGN) SEC 13F Holdings (Q2 2026) — Net Institutional Activity: $166.0M

DSGN ranks #3865 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

DSGN is a top-conviction position for Sr One Capital Management, LP — at 9.1% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

GAMMA Investing LLC has added to its DSGN position for two straight quarters, increasing it by $11.2K to reach $26.8K today.

DSGN is down 1.6% today, but institutions show net buying of $166.0M this quarter — a divergence between today's price move and the underlying institutional flow.

DSGN reported a net loss of $70.8M over the trailing twelve months.

• Not yet profitable — net loss of $70.8M over the trailing twelve months
• Net income declined year over year, from -$63.5M to -$70.8M
• Operating cash flow was negative, using $54.4M in cash
• Current ratio of 17.14x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.06x equity — within a conventional range